
Clerk of the Houge of Representatives Legislative Resource Center B-106 Cannun Building Washington, DC 20515 Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510



00 FEB 14 PM % 53

## LOBBYING REPORT

HAND DELIVERED []

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

I. Rugistrani Naine		
Novartis		
· · · · · · · · · · · · · · · · · · ·	Suite 725 DC 20004	
3. Principal Place of Business (d' different from line 2)		
City State/Zip (or Country)		
4 Couract Name Telephone E-mail Rachel King 262/662-4364	(optional)	5. Sunate iE) #
7. Client Name [] Self.  Novartis Corporation		6. House II) \$ 33\$89000
INCOME OR EXPENSES - Complete Either	Line 12 OR Line 13	
12. Lobbying Firms	13. Organizati	ions
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activity period were:	ties for this reporting
Less than \$10,000 💮	Less than \$10,000 []]	
\$30,000 or more       >> \$	3.0.000 0.3000	48,800.00 pensus (nuaros) \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client	14. REPORTING METHOD. Check accounting method. See instructions for	
(including all payments to the registrant by any other entity	80 Method A. Reporting amounts usin	ng LDA definitions only
for lobbying activities on behalf of the client).	Method B. Reporting amounts und the Internal Revenue C	
·	Method C. Reporting amounts und Internal Revenue Code	
signature foolillely		2/14/60
Printed Name and Title Rachel King - Vice President		Page 1 of 2

Registrant Name:	Novartis	
Client Name:	Novartis Cosporation	
engaged in lobbyit	TIVITY, Select as many codes as necessary to reflect the general issue areas in which the registrant ng on behalf of the client during the reporting period. Using a separate page for each code, provide posted. Attach additional page(s) as needed.	
59 Fed. Reg. Food Qualit Insect Resist Genetically	bying issues  ecticide, Fungicide & Rodenticide Act . 69412 (11/24/96) Atrazine, Simazine and Cyanazine: Notice of Initiation of Special Review ty Protection Act tance Management Engineered Crops Approprations Bill	
Department Environmen	Congress and Federal agencies contacted	
18. Name of eac	h individual who acted as a lobbyist in this issue area  Covered Official Position (if applicable)	New
King, Rache	\(\)	No No
<u> </u>		
Nevartis AC	ach foreign entity in the specific issues fisted on line 16 above   Check if None  G To the degree that public policies, either laws or regulations, commercially benefit Novartis Corpo is AG, as its parent, will benefit.	ration, so
Signature	Date	
	t Title Rachel King - Vice President Page	

Reg	istrant Name:	Novartis		
Clie	nt Name:	Novartis Corporation		
eng.	aged in lobbyin		to reflect the general issue areas in which the registrant specied. Using a separate page for each code, provide	
15.		area code ANI (one per page)		
16.	Specific Lobb	ying issues		
			•	
17.	House(s) of C	ongress and Federal agencies contacted	XI Check if None	
		•		
		•		
18.	Name of each	individual who acted as a lobbyist in this is	sue area	
	Мапне		Covered Official Position (if applicable)	New
				<u> </u>
•••••				
			1,000	
		:		
		'		· · · · · · · · · · · · · · · · · · ·
19.	Interest of ca	ch foreign entity in the specific issues listed	on line 16 above X Check if None	
			·	
Sig	nature		. Date	
Pri	nted Name and	Title Ruchel King - Vice President	Page	3 of 20
			- 70	

gistrant Name:	Novartis		
ent Name:	Novartis Corporation		
gaged in lobbyin		y to reflect the general issue areas in which the registrant ng period. Using a separate page for each code, provide i.	
General issue	e area code <u>BUD</u> (one per page)		
Specific Lobb Appropriatio Administrati			
	Congress and Federal agencies contacted epresentatives	☐ Check if None	·
			٠.
. Name of each	ch individual who acted as a lobbyist in this	issue area	
Name		Covered Official Position (if applicable)	New
Bumbaugh,	Deborah		No
Elkio, Jame	*		No
		\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	
		,	
		•	
Nevartis AC	ach foreign entity in the specific issues liste G To the degree that public policies, cith is AG, as its parent, will benefit.	ed on line 16 above   Check if None  er laws or regulations, commercially henefit Novartis Cos	poration, so
enature	***************************************	Date	
·			

Registrant Name:	Novartis		
Client Name:	Novartis Corporation		
engaged in lobby		to reflect the general issue areas in which the registrant g period. Using a separate page for each code, provide	
15. General issu	e area code CAW (one per page)		•
<ol><li>Specific Lot</li></ol>	bying issues	•	
			• .
			•
17. House(s) of	Congress and Federal agencies contacted	Check if None	
	, J		
			,
		•	
10 - 21	h individual who acted as a lobbyist in this i		
ia. Name of ca	n maiviquai who acted as a loboyist in this i		
	·	2200 1000	
Name	•	Covered Official Position (if applicable)	New
			New
Name	ach foreign entity in the specific issues listed	Covered Official Position (if applicable)	New
Name		Covered Official Position (if applicable)	New
Name		Covered Official Position (if applicable)	New
Name	ach foreign entity in the specific issues lister	Covered Official Position (if applicable)	
Name  19. Interest of a	ach foreign entity in the specific issues listed	Covered Official Position (if applicable)  I on line 16 above	
Name  19. Interest of a	ach foreign entity in the specific issues listed	Covered Official Position (if applicable)	

		rested. Attach additional page(s) as needs area code <u>CHM</u> (one per page		
16.	Food Quality		and Cyanazine: Notice of Inititation of Special Review	
		•		
17.	Department Department Department Environment	of State tal Protection Agency 3 Administration	Check if None	
8.	Name of each	individual who acted as a lobbyist in thi	is issue area  Covered Official Position (if applicable)	New
	Muldoon, Jo			No
		· · · · · · · · · · · · · · · · · · ·		<u> </u>
	•			
<b>19</b> .	Novartis AG	ch foreign entity in the specific issues list To the degree that public policies, eith AG, as its parent, will benefit.	ted on line 16 above — Check if None her laws or regulations, commercially benefit Novartis Corp	oration, s

Registrant Name:	Novartis		
Client Name:	Novartis Corporation		
engaged in lobbying		to reflect the general issue areas in which the registrant g period. Using a separate page for each code, provide	
15. General issue	area code <u>CPT</u> (one per page)		
H.R. 2100, A H.R. 2654, F	bying issues imerican Inventors Protection Act of 199 inti-Tampering Act of 1999, Patent Law Reform Act, 1598, Patent Fairness Act of 1999,	9 <b>,</b>	
17. House(s) of	Congress and Federal agencies contacted	∵ Check if None	
	présentatives		
18. Name of eac	. h individual who acted as a lobbyist in this i	issue area  Covered Official Position (if applicable)	l New
		Control of the contro	
Casserly, Davi			No
Elkia, Jame			No No
man, dame	3		No .
-,			
	· ·		
Novartis A6	nch foreign entity in the specific issues listed To the degree that public policies, either AG, as its parent, will benefit	l on line 16 above	oration, 50
Signature		Date	· · · · · · · · · · · · · · · · · · ·
		Date Page	

tegistrant Name:	Novartis		
lient Name:	Novartis Corporation		
ngaged in lobbyin		y to reflect the general issue areas in which the registrant ng period. Using a separate page for each code, provide i.	·
5. General issue	area code <u>ENV</u> (one per page)		
	ying issues hildren's Environmental Protection and . 1390, Superfund Reform,	Right to Knew Act of 1999,	
	•		
	Congress and Federal agencies contacted presentatives	C) Check if None	
<ol> <li>Name of each</li> </ol>	n individual who acted as a lobbyist in this	issue area	
Name		Covered Official Position (if applicable)	New
Drake, Davi	d	V ************************************	No
		·	
		\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	
			<u> </u>
		3	
			-
Novartis AC	ch foreign entity in the specific issues liste. To the degree that public policies, eithe AG, as its parent, will benefit	d on line 16 above D Check if None er laws or regulations, commercially benefit Novartis Corp	ooration, so
Signature		Date	
-			

. - -

Registrant Name:	Nevartis	
Client Name	Novartis Corporation	
ngaged in lobbyir	CIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant ng on behalf of the client during the reporting period. Using a separate page for each code, provide uested. Attach additional page(s) as needed.	
<ol> <li>General issue</li> </ol>	area code FOO (one per page)	
H.R. 3377, C S. 1155, H.R S. 25t, S. 86 59 Fed. Reg. Food Qualit GMO Label Juice HACC	teguintory Fairness and Openness Act of 1999, Senetically Engineered Food Right to Know Act, . 2129, National Uniformity for Food Act of 1999, B. H.R. 839, H.R. 1145, Country of Origin Labeling, 60412 (11/24/96) Attazine, Simazine and Cynnazine: Notice of Inititation of Special Review y Protection Act	
Department Environmen Food & Dru	Congress and Pederal agencies contacted   Check if None of Agriculture stal Protection Agency g Administration presentatives	
8. Name of eac	h individual who acted as a lobbyist in this issue area	٠.
Name	Covered Official Position (if applicable)	New
Drake, Davi	d	No
Haller, Sara	ih	No .
King, Rache		No
Matdoon, Jo	oe · · · · · · · · · · · · · · · · · · ·	No
<u></u>		
Novartis A	   check if None   To the degree that public policies, either laws or regulations, commercially benefit Novartis Co   AG, as its parent, will benefit.	rporation, su
Signature	Date	
	Title Rachel King - Vice President Pag	

DBRYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant gaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide formation as requested. Attach additional page(e) as neceded.    General issue area code   GOV	egistrant Name:	Nevartis		
gaged in fobbying on behalf of the client during the reporting period. Using a separate page for each code, provide formation as requested.  General issue area code GOV (one per page)  Specific Lobbying issues  II.R. 1778, Federal Election Law Integrity Act of 1999,  S. 746, Regulatory Improvement Act,  House(s) of Congress and Foderal agencies contacted House of Representatives  Senate  Name of each individual who acted as a lobbyist in this issue area  Name Covered Official Position (if applicable) New  Drake, David No  King, Rachel No  No  Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.	lient Name:	Nevartis Corporation		
Specific Lobbying issues H.R. 1778, Federal Election Law Integrity Act of 1999, S. 746, Regulatory Improvement Act,  House(s) of Congress and Federal agencies contacted House of Representatives Senate  Name Covered Official Position (if applicable) New  Drake, David No  King, Rachel No  Interest of each foreign entity in the specific issues listed on line 16 above Check if None  Novartis AG. To the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.	ngaged in lobbyin	g on behalf of the client during the reportin	ng period. Using a separate page for each code, provide	
House(s) of Congress and Federal agencies contacted House(s) of Congress and Federal agencies contacted House of Representatives Senate  Name of each individual who acted as a lobbyist in this issue area  Name   Covered Official Position (if applicable)   New   Drake, David   No   King, Rachel   No    Interest of each foreign entity in the specific issues listed on line 16 above   Check if None   Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.	5. General issue	area code GOV (one per page)	•	
House of Representatives Senate  Name of each individual who acted as a lobbyist in this issue area  Name   Covered Official Position (if applicable)   New    Drake, David   No    King, Rachel   No    No    Interest of each foreign entity in the specific issues listed on line 16 above   Check if None    Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.	H.R. 1778, F	ederal Election Law Integrity Act of 199	9,	
House of Representatives Senate  Name of each individual who acted as a lobbyist in this issue area  Name   Covered Official Position (if applicable)   New    Drake, David   No    King, Rachel   No    No    Interest of each foreign entity in the specific issues listed on line 16 above   Check if None    Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.				
House of Representatives Senate  Name of each individual who acted as a lobbyist in this issue area  Name   Covered Official Position (if applicable)   New    Drake, David   No    King, Rachel   No    No    Interest of each foreign entity in the specific issues listed on line 16 above   Check if None    Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.		•		
House of Representatives Senate  Name of each individual who acted as a lobbyist in this issue area  Name   Covered Official Position (if applicable)   New    Drake, David   No    King, Rachel   No    No    Interest of each foreign entity in the specific issues listed on line 16 above   Check if None    Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.				
House of Representatives Senate  Name of each individual who acted as a lobbyist in this issue area  Name   Covered Official Position (if applicable)   New    Drake, David   No    King, Rachel   No    No    Interest of each foreign entity in the specific issues listed on line 16 above   Check if None    Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.			•	
Name    Covered Official Position (if applicable)   New	House of Re		C Check if None	
Name    Covered Official Position (if applicable)   New				
Name    Covered Official Position (if applicable)   New				
No  No  No  No  No  No  No  No  Noting, Rachel  No  No  Noting, Rachel  No  No  No  Noting, Rachel  No  No  No  No  No  No  No  No  No  N		individual who acted as a lobbyist in this i	1	New
Interest of each foreign entity in the specific issues listed on line 16 above	Drake, Davi	<u>.</u>		No
Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.    Date	King, Rache	[		No.
Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.    Date				
Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.    Date				
Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.    Date			<b></b>	
Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.    Date			}	<u></u>
Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.    Date		<u> </u>		
Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.    Date			I	
	9. Interest of ca	To the degree that public policies, eithe		oration, so
	. Novartis AG	AG, as its parent, will benefit.		
rinted Name and Title Rachet King - Vice President Page 10 of 20	Novartis AC too Nevartis	•		
	Novartis AC too Nevartis	•		

Reg	istrant Name:	Novartis				
Clie	nt Name:	Novartis (	Corporation			
enga	aged in lobbyin	g on behalf	of the client		y to reflect the general issue areas in which the registrant ng period. Using a separate page for each code, provide l.	
	General issue Specific Lobb		<u>HCR</u>	(one per page)		
			•			
					•	,
			•		·	
17.	House(s) of C Drug Enforce Food & Drug House of Reg Senate	ement Adm g Administs	inistration ation	ncies contacted	☐ Check if None	
18.	Name of each	indivídual i	who acted as	e lobbyist in this	issue area  Covered Official Position (if applicable)	New
	Bumbaugh,	Dubuenh		······································	COVICE CIMENT CONTROL (1) apprendice	
	Casseriy, Da			·		No No
	Elkin, James			<del>.</del>		No
	King, Rache	l				No
		1313131333	~•~~··································		<u> </u>	<u> </u>
····	v					<u></u>
۰					23.57	
19.		To the deg	rec that pub	die policies, citho	d on line 16 above — Check if None er laws or regulations, commercially benefit Novartis Corpor	ration, 50
Sig	nature			·····	Date	
Prir	ited Name and	Title Raci	iel King - Vi	ice President	Page	11 of 20

Client N	ame: Novartis Corporation	)n	
Item	Description	Data	
16	Labbying Issues	Showe/Wyden The Seniors Prescription Insurance Coverage Equity Act Breaux/Thomas Medicare Reform Plan Medicare Bi-Partisan Commission Health Insurance Portability and Accessibility Act FDA Modernization Act Pediatric Studies Program Medical Records Privacy- Senators Jeffords, Bennett, Leahy, Kennedy Bills Chairman's Mark (HELP Confidentiality Bills) Xenotransplantation Prospective Payment System	
			٠.
		•	
		·	
	0.000		
	2000 / 000 / 000 / 000		
		•	
		Рад	e 12 of 20

Registrant Name:	Novartis		
Client Name:	Novartls Corporation	·····	
engaged in lobbyin	IVITY. Select as many codes as necessary to re g on behalf of the client during the reporting per ested. Attach additional page(s) as needed.	flect the general issue areas in which the registrant ind. Using a separate page for each code, provide	
<ol> <li>General issue</li> <li>Specific Lobb</li> </ol>	area code LBR (one per page) ying issues	• .	
	• .		
17. House(s) of C	ongress and Federal agencies contacted	18€ Check if None	
18. Name of each	individual who acted as a lobbyist in this issue :		
		FC2	
Name ———		overed Official Position (if applicable)	New
Name ———			New
Name ————————————————————————————————————			New
Name		overed Official Position (if applicable)	New
Name		overed Official Position (if applicable)	New
Name		overed Official Position (if applicable)	New
Name		overed Official Position (if applicable)	New
Name		overed Official Position (if applicable)	New
Name		overed Official Position (if applicable)	New
		overed Official Position (if applicable)	New
		overed Official Position (if applicable)	New
19. Interest of each		ne 16 above   Check if None	

Registrant Name:	Novartis		
Client Name:	Novartis Corporation		
engaged in Iobbyii		o reflect the general issue areas in which the registram period. Using a separate page for each code, provide	
15. General issue			
H.R. 1115/S H.R. 1796, M H.R. 1885/S H.R. 2930, M H.R. 664/S S, 841, (Ken	ledicare Full Access to Cancer Treatment 631, The Immunosuppressive Drug Cover ledicare Chronic Disease Prescription Dru 1191, The International Prescription Druj Jedicare Patlent Access to Medical Techno (31, The Prescription Drug Fairness Act of	rage Act of 1999, ug Benefit Act of 1999, g Parity Act of 1999, plogy Act of 1999, f 1999,	
Department Food & Dru	Congress and Federal agencies contacted of Health & Human Services g Administration presentatives	□ Check if Name	
18. Name of eac Name	ı individual who acted as a lobbyist in this iss	sue area Covered Official Position (if applicable)	New
Humbaugh,	Deburah		No /
Casserly, Da			No
Elkin, Jame			No
. King, Rache	1		No
······		***************************************	
	ş	<u>-</u> ` ,	: !
Novartis AC too Novartis	AG, as its parent, will benefit.	laws or regulations, commercially benefit Novartis Corp	
Novartis AC too Novartii Signature	To the degree that public policies, either AG, as its parent, will benefit.		

Registrant Name:	Novartis		۸.
Client Name:	Nevartis Corporation		
engageð in tobbyir	FIVITY. Select as many codes as necessary ug on behalf of the effent during the reportinuested. Attach additional page(s) as needed	to reflect the general issue areas in which the registrant ag period. Using a separate page for each code, provide,	
<ol> <li>General issue</li> <li>Specific Lobi</li> </ol>	area code <u>NAT</u> (one per page) bying issues		
17. House(s) of (	Congress and Federal agencies contacted	∠ Check if None ∠	•
			•
t8. Name of each	n individual who acted as a lobbyist in this i	issue arça	
Name		Covered Official Position (If applicable)	New
b. 1/1 II			
			_
	<del></del>		
19. Interest of ea	ch foreign entity in the specific issues listed	1 on line 16 above	
Printed Name and	Title Rachel King - Vice President	. Pag	e 15 of 20
	·	•	•

Registrant Name:	Novartis		
Client Name:	Novartis Corporation		
engaged in lobbyin	IVITY. Select as many codes as necessary g on behalf of the client during the reportin ested. Attach additional page(s) as needed.	to reflect the general issue areas in which the registrant g period. Using a separate page for each code, provide	
	area code PHA (one per page)		
<ol><li>Specific Lobb</li></ol>	ying issues		
	•		•
		•	
	•	·	
	•		
17. House(s) of C	ongress and Federal agencies contacted		
	· ·		
18. Name of each	individual who acted as a lobbyist in this i	SSUE BEEZ	
Name		Covered Official Position (if applicable)	New
***************************************			
			Constant of the second
· <u></u>			
	·		, ,
<ol><li>Interest of easier</li></ol>	th foreign entity in the specific issues listed	on line 16 above SI Check if None	-
	•		
Signature		Date	

Registrant Name:	Novartis			
Client Name:	Novartis Corporation			
engaged in lobbyin	IVITY. Select as many codes as necessary g on behalf of the client during the reportinuested. Attach additional page(s) as needed	ig period. Using a separate s		
	area code TAX (one per page) bying issues			
	Congress and Federal agencies contacted presentatives	□ Ch	eck if None	
18. Name of each	i individual who acred as a lobbyist in this	ssue area		
Name		Covered Official Position	ı (îf applicable)	New
Drake, David	d			No
King, Rache	I			No
			VIIIIXXIIIII	
			-	
Novartis AG	ch foreign entity in the specific issues listed To the degree that public policies, eithe AG, as its parent, will benefit.		Check if None sercially benefit Novartis (	Corporation, so
Signature		3	Date	
	Title Ruchel King - Vice President		`	

Registrant Name:	Novartis		
Client Name:	Novartis Cerporation		
engaged in lobbyin	YVITY. Select as many codes as necessary to refluc g on behalf of the client during the reporting period. rested. Attach additional page(s) as needed.		
	ying issues actions		
Department Food & Drug	Congress and Federal agencies contacted of Commerce g Administration presentatives	☐ Check if None	
18. Name of each	individual who acted as a tobbyist in this issue area		
Name	Cove	red Official Position (if applicable)	New
Haller, Sara	1		No
King, Rache	I		No
,		·	******
***************************************			
Novartis AG	ch foreign entity in the specific issues listed on line To the degree that public policies, either laws or AG, as its parent, will benefit.		rporation, so
Signature	·	Date	
	Title Rachel King - Vice President		

legistrant Name:	Novartis		
lient Name:	Novartis Corporation		
ngaged in lobbyi		to reflect the general issue areas in which the registrant ag period. Using a separate page for each ende, provide	
	area code WAS (one per page)		
<ol><li>Specific Lob</li></ol>	oying issues		
	·	•	
	· ·		
	•		
7 House(s) of	Congress and Federal agencies contacted	★ Check if None	
		· · · · · · · · · · · · · · · · · · ·	
	· · · · · · · · · · · · · · · · · · ·		
8. Name of eac	h individual who acted as a lobbyist in this	issue area	
<ol> <li>Name of each Name</li> </ol>	h individual who acued as a lobbyist in this	issue area  Covered Official Position (if applicable)	. New
	h individual who acted as a lobbyist in this		. New
	h individual who acced as a tobbyist in this		New
	h individual who acted as a lobbyist in this		New
	h individual who acted as a tobbyist in this		New
	h individual who acted as a lobbyist in this		New
	h individual who acted as a lobbyist in this	Covered Official Position (if applicable)	New
	h individual who acted as a lobbyist in this	Covered Official Position (if applicable)	New
	h individual who acted as a lobbyist in this	Covered Official Position (if applicable)	New
	h individual who acted as a lobbyist in this	Covered Official Position (if applicable)	New
Name	h individual who acted as a lobbyist in this	Covered Official Position (if applicable)	New
Name		Covered Official Position (if applicable)	New
Name		Covered Official Position (if applicable)	New
Name  Name	sch foreign entity in the specific issues liste	Covered Official Position (if applicable)	
Name  19. Interest of e		Covered Official Position (if applicable)	

istrant Name:	Novarlis				
nt Name:	Novartis Corporation	<u> </u>			
ormation L	pdate Page - Com	plete ONEY where	e registration information has o	hanged.	
Clienti itew addre	TV5			1	
. Client new princ	apal place of business (if diffe	rent from line 20)		·····	
ly	Sta	te/Zip (or Country)			-
New general des	cription of client's business or	activities		••••	
OBBYIST UF 3. Name of each Bentley, List Ailsworth, I	h previously reported in a	dividual who is no l	longer expected to act as a lobby	ist for the client	
	ying issues previously r		ger pertain		
	ORGANIZATIONS owing affiliated organization				
	Name		Address	Principal Place of Bi (city and state or co-	
OREIGN EN	TITIES	ganization that is n	o longer affiliated with the regis	rant or client	
Name	owing foreign entities	Address	Principal Place of Business (city and state or country)	Amount of contribution for lobbying activities	Ownership %
8. Name of eac or affiliated		reign entity that no	longer owns, or controls, or is	iffiliated with the registra	i Ont, client,
gaature	John del	, Y		2/14/00	
inted Name and	Title Rachel King -	tee President			age 20 of 1